Physician profile

Elisa C Yao

Physical Medicine & Rehabilitation · Mountain View, CA

NPI 1164681938

$392.83

in general payments reported to CMS, 2019-2025

8 companies · $164 in 2025

The $164 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).

See the full distribution for Physical Medicine & Rehabilitation

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$164.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Microtransponder, INC. $164.07 2025
Zimmer Biomet Holdings, INC. $70.73 2019
Scilex Pharmaceuticals INC. $46.29 2019
Mdd US Operations, LLC $27.63 2019
Arbor Pharmaceuticals, INC. $24.76 2019
Pfizer INC. $23.56 2019
Electronic Waveform Lab, INC. $19.64 2019
Assertio Therapeutics, INC. $16.15 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Elisa C Yao

$392.83

in general payments reported 2019-2025

Years
2019-2025
Top company
Microtransponder, INC.
Context
The $164 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/908689/elisa-c-yao

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.